The American Association of Tissue Banks accreditation is another significant milestone for Human Regenerative Technologies (HRT) and our partners. Commented Chris Sharp, CEO “We strive to provide the highest quality and most innovative biologics"
Redondo Beach, CA (PRWEB) May 28, 2015
Human Regenerative Technologies, LLC (HRT®) has been awarded the prestigious accreditation of the American Association of Tissue Banks (AATB).
Accreditation follows an intensive review, audit process, including an on-site inspection by a specially trained AATB personal. It establishes that the level of medical, technical, and administrative performance within the facility meets or exceeds the standards set by the AATB.
Obtaining AATB accreditation demonstrates an organization's commitment to the highest standards and to the highest possible level of service to patients and the transplant community. AATB-accredited organizations are recognized as the leaders in their field and as pivotal voices in the dialogue through which consensus-based, voluntary standards are developed and implemented.
"The American Association of Tissue Banks accreditation is another significant milestone for Human Regenerative Technologies (HRT) and our partners. Commented Chris Sharp, CEO “We strive to provide the highest quality and have developed the industry’s most diverse line of active amniotic and placental based biologics utilizing our proprietary HydraTek™ process, and are thrilled to be sharing them with Wound Care, Foot & Ankle, Urology, Podiatry, OB/GYN, ENT, Dental, Oral and Maxillofacial, Orthopedics, Spine, Plastics and Cosmetics communities through our various distribution channels. Our mission continues to be advancing our novel line of placental tissue-based products with the goal of enhancing the quality of patient care in a broad range of clinical applications.”
About Human Regenerative Technologies LLC (HRT) Harnessing the Regenerative Power of the Body®:
Human Regenerative Technologies, LLC (HRT®) is a regenerative biologics company, focused on advancing the understanding and development of human cellular and protein-based therapies through scientific and clinical application.
HRT's commercially available regenerative biologics successfully combines precise science and technology in the procurement, processing and delivery of innovative and novel active Extracellular Matrix (ECM) biologic products derived from human amniotic and placental tissues.
HRT’s advanced HydraTek® process has produced an extensive allograft product offering, including a variety of amniotic membrane configurations, a cryo-preserved flowable placental tissue matrix and the world’s first ambient temperature flowable placental tissue matrix. This patent-pending formulation is the only one of its kind in market, and offers physicians and facilities an off-the-shelf, ready-to-use, viable connective tissue matrix, designed for efficient and precise delivery to the intended site.
HRT is continuing to lead in the advancement and development of novel next-generation amniotic and placental tissue matrix products such as our AmnioPro®45 Membrane, AmnioPro®200 Membrane, AmnioPro®-A Tissue Matrix, and AmnioPro®-C Tissue Matrix, part of a complete portfolio of advanced biologics for many surgical and in-office medical specialties.
HRT continues to expand its national and international distribution network and private label opportunities with synergistic medical companies.
For more information, visit our website at http://www.humantissue.com or email: info(at)humantissue(dot)com
Any forward-looking statement is based on information available to Human Regenerative Technologies LLC as of the date of the statement. All written or oral forward-looking statements attributable to Human Regenerative Technologies LLC are qualified by this caution. HRT does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in HRT’s expectations.